Two new crown oral drugs approved for marketing with conditions; latest WHO statement!

Read Time:7 Minute, 1 Second

Recently, the State Drug Administration, in accordance with the relevant provisions of the Drug Administration Law, conducted emergency review and approval in accordance with the special drug approval procedures, and conditionally approved the Class 1 innovative drug centronavir tablets/ritonavir tablets combination package (trade name: Centronoxin) declared by Hainan Centron Pharmaceutical Co. (trade name: Mindvir) to market.

Both of these drugs are oral small molecule neocoronavirus infection treatment drugs for adult patients with mild to moderate novel coronavirus infection (COVID-19). Patients should use the drugs strictly according to the instructions under the guidance of a physician.

The State Drug Administration requires the holder of the marketing license to continue the relevant research work, complete the requirements of the attached conditions by the deadline, and submit the results of the follow-up study in a timely manner.

Centronavir tablets / ritonavir tablets combination first offer public: 750 yuan / box

On January 30, the official website of Beijing Municipal Medical Security Bureau announced that the first offer of Centronixin, a combination package of Centronoxvir tablets/ritonavir tablets, the first offer of Centronoxvir tablets/ritonavir tablets combination was 750 RMB/box, and the ex-factory price (or import CIF price) including tax was 705-720 RMB/box.

The initial offer was made against nematovir tablets/ritonavir tablets (Paxlovid), monoprevir capsules (Ridzoril), and Azulfidine tablets.

In addition, the announcement disclosed API costs of $334.53 and direct R&D costs of $502,170,000.

Overall national epidemic enters low epidemic level

January 30, the National Health Commission spokesman Mi Feng in a press conference, the Spring Festival, the State Council joint prevention and control mechanism of the relevant departments continue to do a good job of service protection, the majority of medical personnel and workers in various industries to stand firm, prevention and control work is smooth and orderly, “Class B B control” measures on the ground to take effect. At present, the overall national epidemic has entered a low epidemic level, and the epidemic around the country has maintained a steady decline. After the Spring Festival, the flow of people returning to the city has increased, so it is important to do a good job of preventing and controlling the epidemic in crowded places such as transportation and adhere to good personal protection.

No new mutant strains were found to be imported during the Spring Festival

On January 30, Chen Cao, a researcher at the Institute of Viral Diseases of the Chinese CDC, said at a press conference that the current round of the epidemic has BA.5.2 and BF.7 as the main prevalent strains, and no other dominant strains of the virus have been monitored. During the Spring Festival holiday, 1421 whole genome sequences of the new crown virus were received from provinces across the country, and 11 evolutionary branches were found after analysis, still dominated by BA.5.2 and BF.7, and no new mutant strains were found to be imported.

New crown epidemic not yet over

China CDC website January 29 news, China CDC Prevention and Control Center director Shen Hongbing in the new crown infection epidemic level 1 response 66th regular work meeting stressed that the new crown epidemic is not yet over, the virus variation is still uncertain, the next step to start a series of special investigation and research as soon as possible, to provide scientific support for the prevention and control of the epidemic; strengthen the monitoring, especially the monitoring of virus variant strains.

WHO: New crown outbreak remains “a public health emergency of international concern”

The World Health Organization said in a statement on Jan. 30 that although the New Guinea pandemic may be approaching a turning point, it still constitutes a “public health emergency of international concern.

The WHO Emergency Committee held its regular quarterly assessment meeting on the New Crown pandemic on January 27. The WHO said in a statement that the committee had made a series of recommendations to the Director-General on the current situation and future prevention and control of the epidemic, and the Director-General adopted the recommendations and declared on the same day that the new crown outbreak still constitutes a “public health emergency of international concern”. This is the highest level of warning that WHO can issue in accordance with the International Health Regulations.

Committee members expressed concern about the continued risk posed by neostriatal, which continues to cause a high number of deaths compared to other respiratory infections, and that vaccine coverage remains inadequate in low- and middle-income countries and among high-risk groups globally, with uncertainty about the emergence of new variants of the virus.

The committee said the new crown pandemic may be approaching a turning point, but new crown remains a dangerous infectious disease that can cause significant damage to human health and national health systems. Although infection with Neocrown or vaccination may help achieve higher levels of herd immunity globally and limit the impact of morbidity and mortality, Neocrown will remain a persistent pathogen in humans and animals for the foreseeable future.

The Committee calls for long-term public health action to prioritize the reduction of neocon morbidity and mortality.

WHO: “Mixed immunization” provides protection for up to a year

A large-scale study led by the World Health Organization shows that people who have been infected and vaccinated against the new coronavirus have antibodies that protect them from serious illness and hospitalization for longer periods of time, according to a report on Jan. 20 on the website of Singapore’s Union-Tribune.

According to the analysis, published Jan. 18 in the prestigious medical journal The Lancet Infectious Diseases, previous infection and vaccination, or “mixed immunity,” prevented more than 97 percent of serious illnesses or hospitalizations; protection lasted up to 12 months from the time of the most recent infection or vaccination; and booster shots provided an additional 6 months of protection. booster vaccination provides an additional 6 months of protection.

However, for people who receive only two doses of the vaccine, the effectiveness of the antibodies they produce to prevent infection decreases to nearly 42% after one year of illness. For those who received a booster dose, this effectiveness was still more than 46% six months after vaccination.

For unvaccinated individuals, the antibodies they produced after contracting a new crown remained relatively high, at nearly 75%, for protection against serious illness and hospitalization one year after contracting the disease, but their protection against infection diminished to less than 25%.

In Focus

WHO updates list of critical drugs for radiation and nuclear emergencies

On January 27, the World Health Organization (WHO) updated on its website the list of drugs recommended for stockpiling in response to radiation and nuclear emergencies, including drugs to prevent or reduce the effects of radiation, or to treat injuries after radiation exposure. This includes stabilizing iodine, Prussian blue, other drugs used to treat vomiting, diarrhea and infections, etc.

Spotlight

New Features of Jingtong and Beijing HealthBao, Automatic Generation of Nucleic Acid Test Reports in Chinese and English

Beijing has gone online with a Chinese and English nucleic acid testing reporting system, enabling 100% of all nucleic acid test results in the city to be automatically generated in both English and Chinese.

After completing a nucleic acid test at any testing site, if the test result is negative, the public can log on to the “Beijing HealthPop” app and go to “Health Services” – “Beijing Nucleic Acid Test Result Inquiry You can download the latest nucleic acid test report in Chinese and English within three days from the “Health Service” – “Beijing Nucleic Acid Test Result Inquiry” function module. The system generates reports in both English and Chinese by aggregating data from the city’s unified nucleic acid testing system and each laboratory’s own system, and draws on the standardized template for nucleic acid testing reports for Winter Olympics departures to best meet demand.

In Focus

The number of approved innovative drugs falls back in 2022

According to the State Drug Administration’s approval of new drugs listed in Class 1 or Class 1.1, in 2022, China approved a total of 19 innovative drugs to be listed, of which 6 are imported new drugs and 13 are domestic new drugs. According to China Pharmaceutical Industry Information Center, a record 39 new drugs were approved in 2021, and in terms of quantity, the number of new drugs approved in 2022 fell back.